Jolanda Howe Sells 2,500 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,500 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the transaction, the senior vice president now owns 2,426 shares of the company’s stock, valued at approximately $114,264.60. This represents a 50.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mirum Pharmaceuticals Trading Down 3.8 %

Shares of MIRM stock opened at $44.50 on Monday. The business has a 50-day moving average price of $40.12 and a two-hundred day moving average price of $36.15. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $48.89. The company has a quick ratio of 3.09, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The firm has a market cap of $2.14 billion, a P/E ratio of -22.03 and a beta of 1.16.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the previous year, the company posted ($0.57) EPS. Mirum Pharmaceuticals’s quarterly revenue was up 89.4% compared to the same quarter last year. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on MIRM. Citigroup raised their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Evercore ISI upped their price target on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Leerink Partners upped their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $57.73.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently made changes to their positions in MIRM. Quest Partners LLC lifted its stake in Mirum Pharmaceuticals by 7,513.3% in the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after purchasing an additional 1,127 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after buying an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after acquiring an additional 318 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Mirum Pharmaceuticals during the 2nd quarter valued at about $213,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Mirum Pharmaceuticals during the 3rd quarter worth approximately $215,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.